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Summary
The molecular basis of haemophilia B is heterogeneous and
many mutations of the Factor IX (FIX) gene have been characte-
rised. Using the allele-specific arrayed primer extension (AS-
APEX) technology, we have designed a FIX array to simulta-
neously analyse 69 mutations found in British,Thai and Chinese
patients.This technology overcomes the problem of multiple re-
verse dot-blot analysis and has a 100% accuracy in the detection
of both affected subjects and carriers in families with known mu-
tations. In seven unknown mutations from Thailand, the array
could detect the specific mutation in five and in the remainders
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the normal primer at specific spots failed to extend due to a mu-
tation a few nucleotides upstream, thus allowing their identifica-
tion. Hence this FIX array can detect 53% of the 2891 mutation
entries in the FIX database. Each of the microarray slide can be
used for three different test samples and would be useful for car-
rier testing for common mutations and prenatal diagnosis. It is
simpler and more cost effective than genome sequencing and
would be particularly useful in laboratories with limited tech-
nical capabilities.
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Introduction
Haemophilia B (Christmas Disease) is an X-linked coagulo-
pathy due to deficiency of the clotting factor IX (FIX) (1). It af-
fects approximately 1 in 25,000 – 30,000 live-born males (2),
usually females with one defective gene are asymptomatic car-
riers. The molecular basis of the disease is heterogeneous and
over 900 mutations have been characterised (3). While a number
of restriction fragment length polymorphisms (RFLPs) can be
used for linkage of the affected gene in Caucasians (4), in Orient-
als, who lack heterozygosity for these RFLP sites (4–6), carrier
detection and prenatal diagnosis are mainly performed by direct
mutation detection (5).
The development of microarray technology (7) has enabled
large-scale sequence analysis or mutation detection. Employing
the allele-specific arrayed primer extension (AS-APEX) tech-
nology, we have recently devised a microarray for simultaneous
analysis of multiple mutations of the α- and β-globin genes (8).
We now apply the same technology for the manufacture of a
microarray for detecting FIX mutations in known mutants from
three populations as well as those that had been recorded three or
more times on the FIX database. This microarray should be par-
ticularly useful for detection of common mutations, carrier test-
ing in family members of known index patients and in sub-
sequent prenatal diagnosis.
Materials and methods
Genomic DNA were prepared from peripheral blood leucocytes
of 69 unrelated Haemophilia B patients (68 males and 1 female
with FIX = 0.08 iu/ml), 12 known carrier females and 1 normal
female by a phenol-chloroform extraction method (9). These pa-
tients were attending the Haematology clinics at either the Queen
Mary Hospital, Hong Kong; the Ramathibodi Hospital, Bang-
kok, Thailand or the Royal Free Hospital, London, UK. The ge-
notype of the patients had been determined previously by direct
genomic sequencing, but the results were blinded to the scientist
performing the microarray analysis.
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To further validate the usefulness of the fabricated FIX array,
DNA samples from 7 unrelated, new haemophilia B patients
(mutations unknown) and 49 females (38 were relatives of
known mutants and 12 were from new haemophilia B families)
were sent from Thailand. The status of these samples were un-
known to the Hong Kong group and to the laboratory personnel
performing the microarray analysis.
All chemicals and solvents were of analytical grade pur-
chased from Sigma-Aldrich (St. Louis, MO, USA) unless noted
otherwise. Cyanine-labelled deoxycytosine triphosphate
(Cy5-dCTP) was purchased from Amersham Pharmacia Biotech
(Piscataway, NJ, USA). Pre-cleaned, non-derivatised glass
microscope slides (25 x 75mm
2
) were purchased from VWR
Scientific (San Francisco, CA, USA) and LifterSlips were from
Erie Scientific (Portsmouth, NH, USA).
Preparation of slides and array printing
The slides were prepared for printing and the oligonucleotide
primers, approximately 56 basepair in length, with phosphoro-
thioate incorporated at the 5’ terminus and the allele-specific nu-
cleotide at the 3’ terminus were synthesized as described pre-
viously (8, 10). The oligonucleotide primers were designed to
allow detection of known mutations in our initial 69 patients
(primer sequences are available on request). The oligonucleo-
tides were dissolved in 1 x spotting solution (Telechem, Sunny-
vale, CA, USA) at two concentrations of 5 and 2 µM respectively
and spotted onto the slide by contact printing with ‘chipmaker’
pins (Cartesian, Irvine, CA, USA) on the arrayer (Prosys gantry
5510, Cartesian). Each slide contains three sections of oligonu-
cleotides for analysis of three different test samples. In addition,
in each section, the oligonucleotides were spotted in triplicate.
After spotting, the slides were left overnight in the humid
chamber to allow the oligonucleotides to bind onto the glass sur-
face.
Template preparation
Single-stranded template for allele-specific primer extension
was generated by asymmetric amplification of the FIX gene in 7
fragments using either 50 ng (Exons 1, 4, 5 and 6) or 150 ng
(Exons 2+3, 7 and 8) of genomic DNA in a 50 µl reaction volume
containing 1 x PCR buffer (10 mM Tris-HCl pH 8.3, 50 mM
KCl), 3.5 mM MgCl
2
, 40 nM forward primer, 200 nM reverse
primer, 200 µM of each dNTP and 0.5 x BD Titanium Taq (BD
Biosciences Clontech, Palo Alto, CA, USA). After an initial hot-
start of 95°C x 30 sec, 50 cycles amplification of 95°C x 10 sec,
54°C x 20 sec and 68°C x 40 sec were performed, with a final ex-
tension time of 7 min.
All asymmetric-PCR (A-PCR) products were pooled, etha-
nol precipitated and resuspended in 24 µl water and column-
purified (Auto-seq G50, Amersham Pharmacia Biotech, USA)
to remove unincorporated dNTPS. Half of the A-PCR product
was dried and resuspended in 5 µl of water for the analysis.
Allele-specific arrayed primer extension (AS-APEX)
To reduce non-specific binding, the arrayed slide was pre-incu-
bated in 20 µl of 1 x PCR buffer under a LifterSlip (Erie Scien-
tific, USA) in the hybridization cassette (Telechem, USA). The
entire assembly was submerged in a 60°C water bath for 30 min.
The slides were rinsed with water, spun dry at 110 g x 8 min, then
overload with the AS-APEX reaction mix, containing A-PCR
product, 0.25 µM of each dATP, dGTP, dTTP, Cy5-dCTP and
0.125 µM ddNTP, 0.75 x Titanium Taq Polymerase, 10 mM
Tris HCl, 50 mM KCl, 1mM MgCl
2
and 4% DMSO in a total vol-
ume of 15 µl. The entire cassette assembly containing the array
and LifterSlips were transferred to a 75°C water bath for 7 min,
to activate the Titanium Taq Polymerase. The AS-APEX reac-
tion was then allowed to proceed for a further 30 min in a 60°C
water bath. The reaction was terminated by rinsing the slides
three times with water at room temperature and in wash solution
(0.5 x SSC and 0.03% sodium dodecyl sulphate) (1 x SSC =
0.3M NaCl, 0.03M sodium citrate) at 80°C for 2 min, then rinsed
in 0.05 x SSC. After centrifugation (110 g x 8 min), the slides
were scanned at an emission wavelength of 670 nm and 10 µm
resolution for the detection of incorporated Cy5-dCTP (ScanAr-
ray 5000, GSI Lumonics, Boston, MA, USA).
Results
A FIX microarray allowing the detection of 69 mutations was
fabricated. Initially, the array was tested on 82 samples from 69
unrelated Haemophilia B patients whose mutations were already
known and 13 of their female family members. The results are
shown in table 1. The mutations in 35 British, 22 Thai and 12
Chinese patients were correctly identified (accuracy = 100%).At
the same time, 12 female carriers and 1 normal female were cor-
rectly identified.
The sample from a haemophiliac patient carrying a mutation
nt 30929 A→T, gave a positive signal with the mutant oligonu-
cleotide primer, but failed to extend (no signal) with both the nor-
mal primer for nt 30929 and nt 30933 (Fig. 1A). Similar results
were observed for samples from patients carrying a mutation in
close proximity to the next one, e.g., sample with nt 6 mutation
failed to extend the normal primer at nt 6 and nt 8 (Fig. 1C).
Validation of the array using unknown samples
To test the usefulness of the array, a further 56 DNA samples
were sent from Thailand.There were 49 females, 37 were relativ-
es of patients with known FIX mutations. 14 obligate carriers
were correctly identified and 14 out of 23 possible carriers were
identified as carriers by array and confirmed by sequencing. The
remaining nine possible carriers found to be normal by array
analysis were subsequently confirmed as normal by genomic se-
quencing of their FIX gene. FIX:C level of the normal females
were 51–90% whilst that of the carriers were 40–130% (Table
2A). 12 females were relatives of the 7 new haemophilia B pa-
tients whose mutations have not been characterised. FIX:C level
had only been measured in four of these subjects (60–134%). Of
these, four had their carrier status and mutation identified from
the array analysis, and subsequently confirmed as correct by ge-
nomic sequencing. For seven females who were found to be nor-
mal on initial array analysis, sequencing of all eight exons of
their FIX gene and the immediate 5’ and 3’ splice junctions did
not reveal any mutations. The remaining case (N83) was ident-
ified as a carrier by sequencing, with a mutation at nt 6365
(G→T), which was not spotted on our array (vida infra).
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DNA samples of the seven new haemophilia B patients were
analysed. The causative mutations of five patients were ident-
ified by array analysis (Table 2B) and confirmed by sequencing.
In the remaining two patients, their DNA failed to extend the nor-
mal sequence at nt 20519 (G→A) (N67) and nt 6365 (G→A)
(N84) respectively, this indicated that their FIX mutation lies at
or immediately upstream to those regions. Genomic sequencing
of their FIX gene revealed a new mutation at nt 20518 (C→T)
and nt 6365 (G→T) respectively (Fig. 2). In the latter case, his fe-
male relative (N83) was also found by sequencing to be a carrier.
Chan et al.: Factor IX array
874
Nucleotide
Position
Mutation FIX Patients
British Thai
1. –26 G>T 1
2. –6 G>A 1
Chinese
Females
Carrier Normal
3. 6 T>A 1 1
4. 8 ΔT 1
5. 57 ΔGA 1
6. 122 G>C 1
7. 6332 ΔT 1 1
8. 6364 C>T 1 2
9. 6365 G>A 3 2 2 1
10. 6410 G>A 1
11. 6410 G>C 1 2
12. 6443 G>A 1
13. 6460 C>T 1
14. 6461 G>A 1
15. 6464/5 AA>TT 1
16. 6676 A>G
17. 6688 G>A 1
18. 6704 T>G 1
19. 10418 T>C 1
20. 10430 G>A 2
21. 10458 Δ4nts 1
22. 10474 ΔC 1
23. 10478 G>A 1
24. 10479 G>T 1
25. 10506 Δ4nts 1
26. 17680 ΔA 1
27. 17700 C>A 1
28. 17810 A>G 1
29. 20413 C>T 1
30. 20519 G>A 1
31. 20561 G>C 1
32. 20562 G>A 1
33. 30037 A>G 1
34. 30038 G>A 1 1
35. 30076 G>A 1
36. 30150 G>A
37. 30828 A>G 1
38. 30863 C>T
39. 30864 G>A 1
40. 30873 T>A
Table 1: Results of array analysis for the detection of FIX mutations.
Nucleotide
Position
Mutation FIX Patients
68. 31317 C>A 1
69. 31328 C>T 1
TOTAL: 35 22
British Thai
48. 31122 C>A
49. 31127 T>C 1
50. 31127 T>G 1
51. 31133 C>T 1
52. 31136 T>C 1
53. 31152 T>C
54. 31163 A>G 1
55. 31170 G>A 1
56. 31171 T>G 1
57. 31172 G>C
58. 31196 G>A 1
59. 31202 T>C 1
60. 31212 A>T 1
61. 31260 C>G
62. 31260 C>T 1
63. 31261 ΔT
64. 31274 T>C
65. 31289 G>A
66. 31308 G>C 1
67. 31311 T>C
Chinese
1
1
1
1
1
12
Females
Carrier
2
2
12
Normal
1
43. 30933 C>T 1
44. 31008 C>T 1
45. 31070 G>A 1
46. 31118 C>T 1
47. 31119 G>A 1
42. 30929 A>T 1
41. 30875 C>T 1 1
Discussion
In the current FIX array, we have spotted oligonucleotides for the
detection of 69 mutations simultaneously. The majority of these
mutations had been reported at least three times in the FIX data-
base, while others were useful for detection of defects in Hae-
mophilia B patients attending the Haematology clinic at our
three centres. On a theoretical basis, any number (up to 8,000) of
different oligonucleotide primers can be designed and spotted
onto the array, if the entire surface of the slide (50 x 20 mm) is
used for arraying and single test sample analysed on each slide.
With the AS-APEX technology used in our array system, strand
synthesis will only occur with a perfectly matched oligonucleo-
tide and no stringent washing is needed to remove unstable com-
plex as in allele-specific oligonucleotide (ASO) hybridization,
which is the basis of the reverse dot blot (RDB) system. In com-
parison, RDB requires that the oligonucleotide probes be de-
signed to allow hybridization and stringent washing for all the
normal and mutant probes at the same temperature (11). Thus it
would be impossible to design a RDB to detect the over 900 mu-
tations presently identified for the FIX gene.
Since only 0.9 nl of oligonucleotide is arrayed onto each spot
and the glass slide can be easily prepared for spotting, the cost of
preparing our current FIX array in-house is approximately US$
3.00. The array can then be used to analyse three test samples. It
is possible to generate single stranded template for the AS-
APEX reaction directly from genomic DNA by adjusting the
asymmetric primers’ concentration. In our hands, despite the
number of amplification cycles needed, taking standard PCR
precautions as in most routine laboratories that handle patient
samples, no contamination or ‘artificial’generation of mutations
have been encountered. The cost of a sample analysis, including
PCR reagents, AS-APEX reagent such as Cy5-dCTP and Tita-
nium Taq Polymerase is US$ 8.10. This is much cheaper than the
cost of automated sequencing of the whole gene (US$ 90 for un-
known mutation detection, US$ 18 for subsequent carrier detec-
tion). Even if the known mutation alters an enzyme recognition
site and PCR followed by direct restriction analysis is possible,
the analysis using the FIX array would be less time-consuming,
as the entire procedure of PCR and array analysis takes no more
than six hours and also avoids the use of ethidium bromide for
gel-staining which is hazardous to the laboratory staff.
Figure 1: FIX array after hybridization of amplified genomic DNA from haemophilia B patients. The normal and mutant oligonucleotide
primers were spotted in triplicate and at two concentrations, hence the positive signals after the AS-APEX reaction were of dual intensity. a) patient
with mutation at nt 30929, b) A female patient who is heterozygous for the defect but has haemophilia due to skewed inactivation of her normal X
chromosome and c) patient with defect at nt 6.
Chan et al.: Factor IX array
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Table 2A: Array analysis of female relatives of haemophilia B patients.
N61 ND O 31212 + 31212
N73 51 O 6365 + 6365
N77 91 O 20561 + 20561
N91 ND O 31133 + 31133
N10 ND P 31127 - 31127 Normal
N13 90 P 31171 - 31171 Normal
N25 110 P 8 - 8 Normal
N56 51 P 6365 - 6365 Normal
N64 ND P 10458 - 10458 Normal
N70 ND P –26 - –26 Normal
N81 85 P 20519 - 20519 Normal
N92 ND P 31133 - 31133 Normal
N94 ND P 6365 - 6365 Normal
N1 130 P 30864 + 30864
N9 52 P 31127 + 31127
N12 40 P 31171 + 31171
N16 72 P 57/58 + 57/58
N34 25 P 6410 + 6410
N44 72 P 57/58 + 57/58
N58 127 P 31196 + 31196
N59 75 P 31196 + 31196
N72 ND P 31070 + 31070
N75 69 P 6365 + 6365
N80 81 P 20519 + 20519
N95 42 P 6365 + 6365
N96 ND P 6364 + 6364
N100 ND P 20519 + 20519
DNA No. FIX:C Carrier
Status
Mutation of
Haemophilia B patient
Array Analysis Whole Gene
Sequencing Result
Carrier Detection Genotype Identified
N7 48 O 31127 + 31127
N18 110 O 30037 + 30037
N20 80 O 30037 + 30037
N22 104 O 8 + 8
N29 56 O 6365 + 6365
N30 70 O 6365 + 6365
N31 132 O 6410 + 6410
N38 20 O 6365 + 6365
N54 110 O 6460 + 6460
T→G
A→G
A→G
ΔT
G→A
G→A
G→A
G→A
C→T
A→T
G→A
G→C
C→T
T→G
T→G
ΔT
G→A
ΔATGA
G→T
G→A
C→T
G→A
G→A
T→G
T→G
ΔGA
G→A
ΔGA
G→A
G→A
G→A
G→A
G→A
G→A
C→T
G→A
T→G/T
A→G/A
A→G/A
ΔT/T
G→A/G
G→A/G
G→A/G
G→A/G
C→T/C
A→T/A
G→A/G
G→C/G
C→T/C
T
T
T
G
ATGA
G
G
C
G
G→A/G
T→G/T
T→G/T
ΔGA/GA
G→A/G
ΔGA/GA
G→A/G
G→A/G
G→A/G
G→A/G
G→A/G
G→A/G
C→T/C
G→A/G
N5 ND O 10418 T→C + 10418 T→C/T
N107
N105 ND P Unknown + 6365 G→A/G 6365 G→A/G
ND P Unknown + 6365 G→A/G 6365 G→A/G
Chan et al.: Factor IX array
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N49 ND P Unknown - Normal
N50 108 P Unknown - Normal
N106 ND P Unknown - Normal
N110 ND P Unknown - Normal
N112 ND P Unknown - Normal
N117 134 P Unknown - Normal
N119 73 P Unknown - Normal
N83 ND P Unknown - 6365 G→T/G
ND = Not done; O = Obligate; P = Possible; + Positive (carrier female); - Negative (normal female).
DNA No. FIX:C Carrier
Status
Mutation of
Haemophilia B patient
Array Analysis Whole Gene
Sequencing Result
Carrier Detection Genotype Identified
N116 60 P Unknown + 6460 C→T/C 6460 C→T/C
N120 ND P Unknown + 31133 C→T/C 31133 C→T/C
Table 2A: Continued
DNA No. Array Sequencing Mutation Identified
N17 + NR 30037 A→G
N67 +
Mutation around nt 20519
+ 20518 C→T
N84 +
Mutation around nt 6365
+ 6365 G→T
N104 + NR 6365 G→A
N113 + NR 31133 C→T
N115 + NR 6460 C→T
N118 + NR 20519 G→A
NR = Not required; + = Positive result..
Table 2B: Mutation detection for 7 new haemophilia B patients.
Previous experience has shown that the spotted arrays are
stable, can be stored at room temperature and are usable for at
least six months. Thus it would be possible to have the array pre-
pared in a single place and shipped to other laboratories for use,
making it unnecessary for each laboratory to make their own
array. The only requirement then would be a thermocycler and a
laser scanner for detection of emission at a wavelength of 670
nm. This FIX array should be particularly useful for laboratories
in some developing countries who may not wish to go to the ex-
pense of establishing high-throughout sequencing. The tech-
nique is relatively simple, includes generation of single-stranded
template directly by PCR, performing the AS-APEX reaction on
the array, single washing step and laser scanning. It would take
less than a single working day to perform and is relatively cheap
at around US$ 10 for a single sample analysis.
We have tested this FIX array initially on samples from 69
unrelated haemophilia B patients from England, Thailand and
Hong Kong (whose mutations are known and arrayed on the
slide) and some of their female family members (Table 1). It
showed 100% accuracy. In AS-APEX technology, the allele-spe-
cific nucleotide is at the 3’ terminus, resulting in extension and
formation of a coloured (Cy5-labelled) extended product with a
perfectly matched oligonucleotide primer. Thus the absence of
coloured product (signal) with the normal oligonucleotide
primer usually indicates ‘homozygosity’ or in case of a sample
from the male patient, ‘hemizygosity’ or affected subject. One
male with haemophilia had a mutation at nt 30929 A→T, but did
not extend both its own normal oligonucleotide sequence as well
as the normal sequence at nt 30933. The latter was most likely
due to the formation of a ‘bubble’, where the mismatch occurred
four nucleotides upstream, resulting in an unstable annealment
between primer and template and therefore, no extension (Fig.
1A). This also explains the absence of extension in another pa-
tient with nt 6 mutation, for the normal sequence at nt 8 that lies
two nucleotides downstream from the mutation under analysis
(Fig. 1C).
To validate the usefulness of the microarray, we analysed a
further 56 samples from patients and family members from
Thailand. As expected, all 37 females from families with known
mutation had their carrier status correctly determined by the
array. Furthermore, in the seven new haemophilia B families,
five had mutations detectable by the array while in the remaining
two, their mutation was localized to the vicinity of a specific spot
on the array. As discussed previously, this was due to the
formation of an unstable complex between the ‘mutant’ template
and the normal oligonucleotide primer a few nucleotide down-
stream, thus resulting in the absence of extension. Indeed, this
was demonstrated in a sample from a new Thai Haemophilia B
patient (N67) (Fig. 2). His DNA did not give any extension prod-
uct with either the normal or mutant primers at nt 20519. Whilst
this indicated that he did not carry the nt 20519 G→A defect, it
meant that the mutation could be in the vicinity. Genomic se-
quencing of exon f of his FIX gene confirmed a mutation at nt
20518 C→T.
Thus it would be possible to use this array system as an initial
screening technique for new Haemophilia B patients, to identify
the causative mutation or to localize the region of the mutation
along the gene. If undetected on the array, then conventional
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Figure 2: Location of two unknown Haemophilia B mutations by FIX array and their characterisation by genomic sequencing. FIX
array analysis (panels 1 and 3) of amplified genomic DNA from two haemophilia B patients (N67 and N84), showing no extension product for both
normal and mutant probes at nt 20519 and nt 6364 – 6365 respectively. The sequence profile for those respective region of the FIX gene of the two
patients are shown underneath (panels 2 and 4). The normal nucleotide at the mutation site is shown in bold at the top of the sequence.
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genomic sequencing of that particular exonic fragment will
be performed. Based on this approach, the current array
fabricated with 69 oligonucleotide primer sets will allow detec-
tion of 1537 out of the 2891 (53.1%) entries in the FIX database.
Obviously it is possible to make a comprehensive array to detect
all the entries (for over 900 FIX mutations) but it will be more ex-
pensive.
